Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront
Pharmaceutical Business Review
Unanimously approved by both companies' boards, the transaction is expected to close by the fourth quarter (Q4) of 2026, pending customary closing conditions.
pharminent
August 11, 2026 (Last updated: August 11, 2026)
Pharmaceutical Business Review
Unanimously approved by both companies’ boards, the transaction is expected to close by the fourth quarter (Q4) of 2026, pending customary closing conditions.
